Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

508
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
508
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

673
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
673
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

798
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
798
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

939
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
939
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

972
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

773
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
773

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Evolving Role of Eosinophils in Eosinophilic Esophagitis: Mechanisms, Crosstalk, and Therapeutic Perspectives.

Cells·2026
Same author

Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

Journal of hepatology·2026
Same author

Feasibility and safety of an adaptive endoscopic resection algorithm guided by the muscle-retracting sign for early rectal cancer.

Endoscopy·2026
Same author

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Advances in therapy·2026
Same author

The Gut-Vagina Axis.

Microorganisms·2026
Same author

Innovations in Advanced Endoscopic Resection of Early Upper Gastrointestinal Cancer.

Journal of clinical medicine·2026

相关实验视频

Updated: Feb 28, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.5K

腹管理:从病理生理学到微生物群调节

Giovanni Marasco1,2, David Meacci1,2, Giovanni Sarnelli3

  • 1IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.

Therapeutic advances in gastroenterology
|February 26, 2026
PubMed
概括

腹,无论是急性还是慢性,有许多影响全球健康的原因. 在许多腹病例中,肠道微生物群的改变 (失生症) 是关键因素,影响诸如益生菌和便微生物群移植等治疗策略.

关键词:
急性腹急性腹是什么抗生素 抗生素是一种抗生素.慢性腹 慢性腹 慢性腹这是一种多样性疾病 (diverticular disease).这种疾病叫做dysbiosis.便微生物群移植我们的肠道微生物群.炎症性肠病是一种炎症性肠病.刺激性肠综合征是什么意思益生菌 益生菌 益生菌益生菌是一种益生菌.小肠细肠细菌过度生长细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细肠细细肠细肠细肠细肠细细肠细肠细肠细细肠细肠细细细肠细肠细细细细肠细细细肠细细细肠细细细肠细细细细细细细细细细

更多相关视频

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

相关实验视频

Last Updated: Feb 28, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.5K
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

科学领域:

  • 胃肠病学 胃肠病学
  • 微生物学 微生物学
  • 内部医学 内部医学

背景情况:

  • 腹,无论是急性还是慢性,是一种普遍的疾病,对全球健康和经济产生重大影响.
  • 它根据持续时间 (急性<2周,慢性>4周) 和病理生理学 (透性,分泌性,炎症性,运动性相关) 进行分类.
  • 肠道微生物群失调是各种急性和慢性腹病因的常见因素.

研究的目的:

  • 审查急性和慢性腹的普遍原因和机制.
  • 强调肠道微生物群在腹病原发生中的关键作用.
  • 检查针对肠道微生物群调节的治疗策略.

主要方法:

  • 关于急性和慢性腹的文献综述.
  • 专注于病理生理机制.
  • 分析肠道微生物群的作用和治疗干预措施.

主要成果:

  • 急性腹往往源于传染性胃肠炎与暂时的失生症.
  • 慢性腹涉及复杂的病因和持久性失生症,在像IBS这样的疾病中见到.
  • 失生症是不同原因导致腹的统一特征.

结论:

  • 了解腹机制,特别是肠道微生物群的参与,对于有效的管理至关重要.
  • 诸如益生菌,益生菌和便微生物群移植等治疗策略显示出对调节肠道微生物群的承诺.
  • 对微生物向治疗的进一步研究可以改善急性和慢性腹患者的治疗结果.